'Maintenance rituximab' diaporamas de présentation

E1496: ECOG and CALGB

E1496: ECOG and CALGB. Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent Lymphoma Patients: Results from the E1496 Trial Howard S. Hochster Edie Weller Randy D. Gascoyne Theresa S. Ryan Thomas M. Habermann Leo I. Gordon Stanley R. Frankel

542 views • 26 slides

Kahl BS et al. Proc ASH 2012; Abstract 153.

253 views • 11 slides

Salles GA et al. Proc ASCO 2010;Abstract 8004.

Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy. Salles GA et al. Proc ASCO 2010;Abstract 8004. Introduction.

258 views • 11 slides

Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496)

R A N D O M I Z E. Observation (OBS) vs Rituximab Maintenance (MR). CVP x 6-8 ? PR/CR (cyclophosphamide, vincristine, prednisone). Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496). Subset: 237 FL pts. P = .03 (one-sided).

230 views • 6 slides